Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 30,654 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $240.74, for a total value of $7,379,643.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Xiaobin Wu also recently made the following trade(s):
- On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69.
Beigene Stock Performance
Shares of NASDAQ ONC opened at $255.37 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a 52 week low of $126.97 and a 52 week high of $260.98. The firm has a market capitalization of $24.99 billion, a P/E ratio of -30.99, a P/E/G ratio of 7.73 and a beta of 0.63.
About Beigene
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Further Reading
- Five stocks we like better than Beigene
- What is a buyback in stocks? A comprehensive guide for investors
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Industrial Products Stocks Investing
- DuPont’s Electronics Spinoff: The Start of Something Big
- Technology Stocks Explained: Here’s What to Know About Tech
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.